Real-world effectiveness of prophylactic tixagevimab-cilgavimab monoclonal antibodies on incidence and severity of COVID-19 infection in patients with cancer

被引：0
|
作者：
Naser, Maryam [1 ]
Bhardwaj, Prarthna V. [1 ]
Warriach, Fatima Zahid [1 ]
Jadoon, Yamna [1 ]
Gupta, Kush [1 ]
Rastegar, Vida [1 ]
Loke, Chandravathi [1 ]
Malleshappa, Sudeep Kumar Siddappa [1 ]
机构：
[1] Univ Massachusetts, Chan Med Sch Baystate, Springfield, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18843
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Observational study of COVID-19 prophylactic antibody (tixagevimab/cilgavimab) administration for multiple myeloma patients
    Lee, Yoojin
    Jo, Jae-Cheol
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S298 - S298
  • [22] Tixagevimab and Cilgavimab: Can we see More Recommendations for Monoclonal Antibodies Beyond COVID-19 Vaccination
    Anmar, Al-Taie
    DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS, 2022,
  • [23] Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan
    Mizuki Haraguchi
    Hisashi Yamamoto
    Otoya Watanabe
    Takashi Sakoh
    Keiko Ishida
    Sho Ogura
    Masayo Katoh-Morishima
    Yuki Taya
    Aya Nishida
    Daisuke Kaji
    Shinsuke Takagi
    Go Yamamoto
    Naoyuki Uchida
    Hideki Araoka
    Bone Marrow Transplantation, 2023, 58 : 1051 - 1053
  • [24] Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan
    Haraguchi, Mizuki
    Yamamoto, Hisashi
    Watanabe, Otoya
    Sakoh, Takashi
    Ishida, Keiko
    Ogura, Sho
    Katoh-Morishima, Masayo
    Taya, Yuki
    Nishida, Aya
    Kaji, Daisuke
    Takagi, Shinsuke
    Yamamoto, Go
    Uchida, Naoyuki
    Araoka, Hideki
    BONE MARROW TRANSPLANTATION, 2023, 58 (09) : 1051 - 1053
  • [25] SYSTEMATIC REVIEW OF THE CLINICAL EFFECTIVENESS OF TIXAGEVIMAB/CILGAVIMAB FOR PROPHYLAXIS OF COVID-19 IN IMMUNOCOMPROMISED PATIENTS
    Suribhatla, Rhea
    Starkey, Thomas
    Ionescu, Maria C.
    Lee, Lennard Y.
    RHEUMATOLOGY, 2023, 62
  • [26] Efficacy of tixagevimab/cilgavimab as preexposure prophylaxis to prevent symptomatic COVID-19 infection in Multiple Sclerosis and Related Disorders: a real-world observational study
    Tan, Christina
    Locke, Laura
    Sati, Pascal
    Guerrero, Brooke
    Sicotte, Nancy
    Al-Louzi, Omar
    NEUROLOGY, 2023, 100 (17)
  • [27] Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis
    Hall, V. G.
    Lim, C.
    Saunders, N. R.
    Klimevski, E.
    Nguyen, T. H. O.
    Kedzierski, L.
    Seymour, J. F.
    Wadhwa, V.
    Thursky, K. A.
    Yong, M. K.
    Kedzierska, K.
    Slavin, M. A.
    Teh, B. W.
    LEUKEMIA & LYMPHOMA, 2023,
  • [28] Retrospective Analysis of a Real-Life Use of Tixagevimab-Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19
    Capoluongo, Nicolina
    Mascolo, Annamaria
    Bernardi, Francesca Futura
    Sarno, Marina
    Mattera, Valentina
    di Flumeri, Giusy
    Pustorino, Bruno
    Spaterella, Micaela
    Trama, Ugo
    Capuano, Annalisa
    Perrella, Alessandro
    PHARMACEUTICALS, 2023, 16 (10)
  • [29] Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19
    Webb, Brandon J.
    Buckel, Whitney
    Vento, Todd
    Butler, Allison M.
    Grisel, Nancy
    Brown, Samuel M.
    Peltan, Ithan D.
    Spivak, Emily S.
    Shah, Mark
    Sakata, Theadora
    Wallin, Anthony
    Stenehjem, Eddie
    Poulsen, Greg
    Bledsoe, Joseph
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (07):
  • [30] COVID-19 antibody titers after tixagevimab-cilgavimab injection in patients with hematologic diseases; a single-center, prospective study
    Nakamura, Naokazu
    Tsunemine, Hiroko
    Ikunari, Ryo
    Sakai, Tomomi
    Arima, Nobuyoshi
    LEUKEMIA & LYMPHOMA, 2024, 65 (08) : 1117 - 1126
12345